The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Update from MURANO trial: venetoclax-rituximab leads to slower clonal growth rate in CLL
Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, discusses results from a minimal residual disease (MRD) model from the Phase III MURANO trial (NCT02005471). The trial compared venetoclax and rituximab with bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Results from the trial have previously reported that fixed-duration treatment without any chemotherapy has resulted in improved progression-free survival and overall survival. The latest results report that post-treatment MRD levels were found to be significantly lower in patients receiving venetoclax and rituximab by slowing the growth of the residual disease clones. Prof. Kater also discusses reasons why patients experience relapse after the fixed-duration treatment has concluded. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
